Replies to post #708106 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Nemesis18,

Bankruptcy is not the issue anymore but unwanted take over has been. Glad you bring this up again because those that want NWBO to fail or be bought out cheap are “getting desperate” and their noise is approaching a fevered pitch; ). Best wishes.

[dstock07734]

Next time you think about bankruptcy, read this figure. These are all the targets (highly overexpressed genes on cancer cells) adopted for current ADCs either approved or in trial. Dendritic cells primed and educated by the technology owned by NWBO can spot highly overexpressed mutated genes on cancer and fix them, which is not surprising since there is no one else who knows the immune system better than the commander of the immune system.



Now you should know why AZN let Timothy Cloughesy run a trial on rGBM using Tagrisso which targets EGFR.
https://clinicaltrials.gov/study/NCT03732352

Here is a partial list of ADC acquisition. If Merck is going to use DCVax-L as a platform doing target identification for ADCs, without doubt other companies would do the same in order to be competitive.

Again for NWBO, all it matters is science and everything else is just noise.

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
https://investor.immunogen.com/news-releases/news-release-details/abbvie-acquire-immunogen-including-its-flagship-cancer-therapy


Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb
https://www.orumrx.com/news/orum-orm-6151-acquisition-by-bms

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
https://tubulis.com/news/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients-2/


Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs
https://www.merck.com/news/daiichi-sankyo-and-merck-announce-global-development-and-commercialization-collaboration-for-three-daiichi-sankyo-dxd-adcs/

Merck Snaps Up Small Startup in $208M Deal, Seeks to Improve Safety of ADCs
https://www.biospace.com/merck-snaps-up-small-startup-in-208m-deal-seeks-to-improve-safety-of-adcs


GSK enters exclusive license agreement with Hansoh for HS-20089
https://www.gsk.com/en-gb/media/press-releases/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20089/


LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
https://www.prnewswire.com/news-releases/lanova-medicines-announces-global-exclusive-license-agreement-with-astrazeneca-for-lm-305-a-novel-gprc5d-targeting-antibody-drug-conjugate-301823364.html


Eli Lilly expands ADC scope with Mablink Bioscience acquisition
https://www.pharmaceutical-technology.com/news/eli-lilly-expands-adc-scope-with-mablink-bioscience-acquisition/

Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry
https://www.biopharmadive.com/news/genmab-profoundbio-adc-acquisition-buyout-seagen/712097/


Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
https://www.janssen.com/johnson-johnson-acquire-ambrx-advancing-next-generation-antibody-drug-conjugates-transform-treatment

[biosectinvestor]

I stated facts, you took something typical and exaggerated the meaning.